Gyre Therapeutics (GYRE) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Verastem (VSTM) over the past year, losing 7.4% versus a loss of 9.3%. Over five years, VSTM leads with a -75.5% price change compared with -88.7% for GYRE. Verastem is the larger company by market cap ($734.5 million vs $716.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | VSTM |
|---|---|---|
| Share price | $6.76 | $8.11 |
| Market cap | $716.79M | $734.47M |
| 1-day change | -3.98% | -1.88% |
| YTD return | -4.25% | +5.05% |
| 1-year return | -7.40% | -9.28% |
| 5-year return | -88.73% | -75.51% |
| Forward P/E | 112.67 | — |
| EPS (TTM) | $-0.25 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $10.82 |
| 52-week low | $5.44 | $3.43 |
| Distance from 52-week high | -28.24% | -25.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.18% | +84.96% |
| Average volume | 105.93K | 2.25M |
| Shares outstanding | 106.03M | 90.56M |
| Employees | 625 | 102 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Gyre Therapeutics in Health Care and Verastem in Healthcare.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
GYRE vs VSTM FAQ
Which is bigger, Gyre Therapeutics or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $734.47M compared with $716.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or VSTM?
GYRE returned -7.40% over the past 12 months, compared with -9.28% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Verastem in the same industry?
No. Gyre Therapeutics is in the Health Care sector, while Verastem is in Healthcare.